Aldosterone synthase inhibitors: Pharmacological and clinical aspects

Current Opinion in Investigational Drugs

Volumn 10, Issue 4, 2009, Pages 319-326

  Jansen, Pieter M ^a   Van Den Meiracker, Anton H ^a   Jan Danser, A H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aldosterone synthase; angiotensin II; CYP11B1; hypertension; mineralocorticoid receptor; non genomic effect

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ALDOSTERONE SYNTHASE; ANGIOTENSIN RECEPTOR ANTAGONIST; AROMATASE INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIGOXIN; FAD 286; FADROZOLE; LOSARTAN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; BREAST CANCER; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; ENZYME ACTIVITY; ENZYME STRUCTURE; HEART FAILURE; HUMAN; HYPERTENSION; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYNTHESIS;

ADRENAL CORTEX; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ALDOSTERONE SYNTHASE; ANIMALS; CHOLESTEROL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; RECEPTORS, ALDOSTERONE;

EID: 63849278169     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Dzau VJ, Colucci WS, Hollenberg NK, 1. Williams GH: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation (1981) 63(3):645-651.
2. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S: Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation (2007) 115(13):1754-1761.
3. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 25(4):292-299.
4. Jansen PM, Boomsma F, van den Meiracker AH, Dutch ARRAT Investigators: Aldosterone-to-renin ratio as a screening test for primary aldosteronism - The Dutch ARRAT Study. Neth J Med (2008) 66(5):220-228.
5. Jansen PM, Danser AHJ, Imholz BP, van den Meiracker AH: Aldosterone receptor antagonism in hypertension. J Hypertens (2009): in press.
6. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol (2007) 3(9):486-492.
7. Young MJ: Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens (2008) 17(2):174-180.
8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol (2005) 45(8):1243- 1248.
9. Strauch B, Petrak O, Wichterle D, Zelinka T, Holaj R, Widimský J Jr: Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens (2006) 19(9):909-914.
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 348(14):1309-1321.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 341(10):709-717.
12. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA: Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med (2008) 168(1):80-85.
13. Jeunemaître X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Ménard J: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol (1987) 60(10):820-825.
14. Chai W, Danser AHJ: Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol (2006) 374(3):153-162.
15. Skatt O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL: Rapid actions of aldosterone in vascular health and disease - friend or foe? Pharmacol Ther (2006) 111(2):495-507.
16. Schiffrin EL: Effects of aldosterone on the vasculature. Hypertension (2006) 47(3):312-318.
17. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AHJ: Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension (2005) 46(4):701-706.
18. Khalil RA: Sex hormones as potential modulators of vascular function in hypertension. Hypertension (2005) 46(2):249-254.
19. Connell JM, Davies E: The new biology of aldosterone. J Endocrinol (2005) 186(1):1-20.
20. Bassett MH, White PC, Rainey WE: The regulation of aldosterone synthase expression. Mol Cell Endocrinol (2004) 217(1-2):67- 74.
21. 2+ fluxes in bovine adrenal glomerulosa cells. Proc Natl Acad Sci USA (1981) 78(5):3044-3048.
22. 2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol (2008) 584(2-3):424-434.
23. + stimulated aldosterone secretion. Mol Cell Endocrinol (2001) 175(1-2): 157-171.
24. 2+-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases. Endocrinology (1997) 138(2):835-838.
25. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE: Calmodulindependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology (2002) 143(9):3651-3657.
26. Kakiki M, Morohashi K, Nomura M, Omura T, Horie T: Expression of aldosterone synthase cytochrome P450 (P450aldo) mRNA in rat adrenal glomerulosa cells by angiotensin II type 1 receptor. Endocr Res (1997) 23(4):277-295.
27. Bird IM, Pasquarette MM, Rainey WE, Mason JI: Differential control of 17α-hydroxylase and 3β-hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. J Clin Endocrinol Metab (1996) 81(6):2171-2178.
28. Romero DG, Welsh BL, Gomez-Sanchez EP, Yanes LL, Rilli S, Gomez-Sanchez CE: Angiotensin II-mediated protein kinase D activation stimulates aldosterone and cortisol secretion in H295R human adrenocortical cells. Endocrinology (2006) 147(12):6046-6055.
29. 2+ influx. Mol Cell Endocrinol (2001) 177(1-2):61-70.
30. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE: The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Mol Endocrinol (2004) 18(2):279-290.
31. Kurihara I, Shibata H, Kobayashi S, Suda N, Ikeda Y, Yokota K, Murai A, Saito I, Rainey WE, Saruta T: Ubc9 and protein inhibitor of activated STAT 1 activate chicken ovalbumin upstream promoter-transcription factor I-mediated human CYP11B2 gene transcription. J Biol Chem (2005) 280(8):6721-6730.
32. Bassett MH, Zhang Y, White PC, Rainey WE: Regulation of human CYP11B2 and CYP11B1: Comparing the role of the common CRE/Ad1 element. Endocr Res (2000) 26(4):941-951.
33. Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyahara K, Miura S, Ohnishi T, Ichikawa Y, Nakao K, Imura H: Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA (1992) 89(4):1458-1462.
34. Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, de Gooyer M, Smits JF, Beugels I, Emmen J, Ottenheijm HC et al: Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des (2007) 21(8):455-471.
35. Bottner B, Schrauber H, Bernhardt R: Engineering a mineralocorticoid- to a glucocorticoid-synthesizing cytochrome P450. J Biol Chem (1996) 271(14):8028-8033.
36. Kau MM, Kan SF, Wang JR, Wang PS: Inhibitory effects of digoxin and ouabain on aldosterone synthesis in human adrenocortical NCI-H295 cells. J Cell Physiol (2005) 205(3):393-401.
37. Demers LM, Melby JC, Wilson TE, Lipton A, Harvey HA, Santen RJ: The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J Clin Endocrinol Metab (1990) 70(4):1162-1166.
38. Hartmann RW, Müller U, Ehmer PB: Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur J Med Chem (2003) 38(4):363-366.
39. Bureik M, Hübel K, Dragan CA, Scher J, Becker H, Lenz N, Bernhardt R: Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol Cell Endocrinol (2004) 217(1-2):249-254.
40. Ulmschneider S, Muller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD, Bureik M, Bernhardt R, Antes I, Lengauer T: Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: Potent inhibitors of aldosterone synthase. J Med Chem (2005) 48(6):1796-1805.
41. Muller-Vieira U, Angotti M, Hartmann RW: The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11β-hydroxylase) inhibitors. J Steroid Biochem Mol Biol (2005) 96(3-4):259-270.
42. Voets M, Muller-Vieira U, Marchais-Oberwinkler S, Hartmann RW: Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids. Arch Pharm (Weinheim) (2004) 337(7):411-416.
43. Voets M, Antes I, Scherer C, Muller-Vieira U, Biemel K, Barassin C, Marchais-Oberwinkler S, Hartmann RW: Heteroaryl-substituted naphthalenes and structurally modified derivatives: Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem (2005) 48(21):6632-6642.
44. Voets M, Antes I, Scherer C, Muller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: Potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem (2006) 49(7):2222-2231.
45. Ulmschneider S, Muller-Vieira U, Klein CD, Antes I, Lengauer T, Hartmann RW: Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/- indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase. J Med Chem (2005) 48(5):1563-1575.
46. Ulmschneider S, Negri M, Voets M, Hartmann RW: Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg Med Chem Lett (2006) 16(1):25-30.
47. Lucas S, Heim R, Negri M, Antes I, Ries C, Schewe KE, Bisi A, Gobbi S, Hartmann RW: Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem (2008) 51(19):6138-6149.
48. Heim R, Lucas S, Grombein CM, Ries C, Schewe KE, Negri M, Muller-Vieira U, Birk B, Hartmann RW: Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: Influence of heteroaryl derivatization on potency and selectivity. J Med Chem (2008) 51(16):5064-5074.
49. Ménard J, Gonzalez MF, Guyene TT, Bissery A: Investigation of aldosterone-synthase inhibition in rats. J Hypertens (2006) 24(6):1147-1155.
50. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus 50. G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY et al: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation (2005) 111(23):3087-3094.
51. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL et al: Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: A comparison with spironolactone. Eur Heart J (2008) 29(17):2171-2179.
52. Chai W, Garrelds IM, de Vries R, Danser AHJ: Cardioprotective effects of eplerenone in the rat heart: Interaction with locally synthesized or blood-derived aldosterone? Hypertension (2006) 47(4):665-670.
53. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE: Origin of aldosterone in the rat heart. Endocrinology (2004) 145(11):4796-4802.
54. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE: Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab (2005) 288(2):E342-E346.
55. + in Wistar rats. Am J Physiol Regul Integr Comp Physiol (2008) 295(1):R166-R172.
56. Huang BS, White RA, Ahmad M, Tan J, Jeng AY, Leenen FHH: Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovasc Res (2009) 81(3):574-581.
57. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JMJ, Danser AHJ: Genomic and nongenomic effects of aldosterone in the rat heart: Why is spironolactone cardioprotective? Br J Pharmacol (2005) 145(5):664-671.